High indicators of small cell lung cancer mostly refer to high levels of NSE and ProGRP in clinical practice. It is recommended to consult a doctor to clarify whether there is recurrence or metastasis of the disease. Surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc. can be chosen in accordance with medical advice. NSE refers to neuron-specific enolase, which is of high diagnostic significance and relatively high specificity for diagnosing small cell lung cancer. Most of the patients with small-cell lung cancer will have a gradual decrease in this index after treatment, and when it rises again, it is necessary to be alert to the recurrence or metastasis of small-cell lung cancer. ProGRP refers to gastrin-releasing peptide precursor, which is a commonly used serum tumor marker for small-cell lung cancer and is positively correlated with its stage. For small cell lung cancer patients, most of the clinical choices are radiotherapy and chemotherapy, and the radiotherapy and chemotherapy regimens are different according to the different tumor stages. Clinically, immunotherapy can also be tried, which has certain therapeutic effect. Immunotherapy can be chosen from tirilizumab, karelizumab, and anti-tumor angiogenesis targeted drugs, such as erlotinib hydrochloride, which have better therapeutic effect on small-cell lung cancer. However, the specific treatment method as well as the use of drugs should be carried out under the guidance of doctors, and should not be treated blindly on one’s own. Patients with high indicators of small cell lung cancer should be especially alert to the recurrence or metastasis. If there is any discomfort, consult a doctor in time and follow the doctor’s instruction.